Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Omeros: Ophthalmology Drug OMS302 Met Primary, Secondary Goals In Phase 3 Trial

RELATED NEWS
Trade OMER now with 

Omeros Corp. (OMER: Quote) said its ophthalmology product OMS302 met its primary and secondary end points in Phase 3 clinical trial in patients undergoing intraocular lens replacement surgery.

According to the company, OMS302 achieved its primary endpoint by demonstrating statistically significant maintenance of intraoperative mydriasis, also called pupil dilation. OMS302 also showed statistical superiority over placebo in reduction of pain in the early postoperative period. The data for both endpoints are clinically meaningful.

OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.

"...This achievement marks our transition to a company preparing, rather than hoping, to commercialize our first product," said Gregory Demopulos, chairman and chief executive officer of Omeros. "Following our recent successful meetings with U.S. and European regulators, we plan to begin enrolling patients in our second Phase 3 trial early next month and to submit marketing applications in both the U.S. and Europe in the first part of 2013."

Register
To receive FREE breaking news email alerts for Omeros Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Australia's international cricketer Phillip Hughes, who sustained critical injury after being hit on the head by a ball during a domestic match Tuesday, has died. The 25 year-old promising player had been fighting for his life for two days at St Vincent's Hospital in Sydney, in induced coma. Australian cricket team's doctor Peter Brukner said at a news conference Thursday that Hughes died as a After turning in a lackluster performance for much of the session, stocks managed to end Wednesday's trading mostly higher. The gains lifted the Dow and the S&P 500 to new record closing highs, while the Nasdaq reached its best levels since 2000. Half of Americans agree with the changes to immigration policy announced by President Barack Obama last week, according to a CNN/ORC poll, although a majority opposes using executive orders to implement those policies.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.